March 30, 2001 — CENTENNIAL, CO — In a strategic move to meet the increasing demand for human allografts nationwide, AlloSource, one of the largest non-profit tissue bank cooperatives, has opened its new state-of-the-art facility.
Officially opened on March 29, the new space allows AlloSource the opportunity to more than double its tissue processing capabilities and houses Class 100 cleanrooms.
AlloSource is the first national tissue network where all facets of bone and tissue recovery are entirely American Association of Tissue Banks (AATB) accredited and non-profit in nature. The new facility is located in Centennial and features a USP water system and other design features to help meet future FDA regulations. Additionally, the facility’s advanced technology enables AlloSource to immediately increase its production of core products (demineralized bone matrix, traditional grafts and structural grafts), as well as explore other opportunities for expanding its services into specialized areas.
AlloSource recently appointed Thomas A. Cycyota as its president and chief executive officer. In this role, Cycyota is responsible for directing the overall operational activities of AlloSource, including all processing, distribution and quality aspects of the organization. With over 20 years of experience in the medical device industry, Cycyota’s expertise complements the company’s mission to assure the highest quality in the products AlloSource provides to its customers.
“Opening our new facility is an exciting development for the company and the industry,” Cycyota said. “The advanced capabilities our facility provides will not only help to increase production, but also create additional opportunities to further the life enhancing benefits of allografts.”
As part of the grand opening festivities, AlloSource hosted a special dedication event at the new location, inviting key dignitaries, customers, hospital and medical representatives, to join its employees in the celebration.
“We look forward to working with several organ procurement organizations to identify more opportunities and developments in bone and tissue recovery,” Cycyota said. “Our reputation as one of the leaders in our field will be further reinforced through our facility expansion and extension of our allograft products into more specialized application.”